While there is general consensus within the pharmaceutical industry on the importance of providing plain language summaries (PLS) of clinical trial results to participants and the public as a whole, two of the largest regulatory agencies ― the European Medicines Agency and the Food and Drug Administration ― differ on their approach to the matter.
Download
